Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Third-party NDA reviews advocated in NDMA testimony to House subcommittee.

This article was originally published in The Tan Sheet

Executive Summary

NDMA "STRONGLY SUPPORTS" THIRD-PARTY OTC REVIEW by "accredited independent authoritative review organizations," according to the Nonprescription Drug Manufacturers Association's written testimony to the House Commerce Committee's health subcommittee. The testimony, part of a May 1-2 hearing on FDA reform legislation, generally supports the OTC-related provisions in HR 3199.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS085365

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel